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Acinetobacter baumannii is an opportunistic pathogen which has been implicated 
in a variety of nosocomial infections among immunocompromised patients worldwide. 
Recently, Multi-drug resistant (MDR) isolates of A. baumannii have been isolated from 
military personnel returning from service in Iraq and Afghanistan. Antibiotic resistance of 
A. baumannii has limited the number of active antibacterial, making very difficult to treat 
these types of infections. This work investigated the role of Resistance-Nodulation-cell 
Division (RND) efflux pumps in the antibiotic resistance mechanism of A. baumannii. 
Expression of six different RND pumps was analyzed in clinical isolates of A. baumannii. 
A novel RND family pump, AdeMNO, was found to be present in a majority of isolates. 
The adeMNO operon was cloned, sequenced, and characterized using the single copy 
gene expression system in an efflux sensitized surrogate Pseudomonas aeruginosa 
strain. Antibiotics, trimethoprim, chloramphenicol, and clindamicin were identified as the 
substrates of this pump. In order to understand the mechanisms of regulation of adeMNO 
operon, a putative regulator belonging to the lysR-family was identified, cloned, and 
sequenced from the upstream region of the operon. Promoter regions of the adeMNO 
operon were also sequenced from various clinical isolates and sequence polymorphisms 
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1.1. Acinetobacter baumannii 
Acinetobacter baumannii is a non fermentative, Gram-negative, non-motile rod-
shaped bacterium that has become a recurrent microorganism present on the skin of 
healthy individuals, especially healthcare personnel. There is a great diversity within the 
genus Acinetobacter making differentiation of species difficult; however, A. baumannii is 
the specie most commonly isolated from health care facilities and it is responsible for 
80% of the infections reported in Intensive Care Units (Cisneros et al., 1996; Fournier and 
Richet, 2006; French, 1980).  
 For many years the Genus Acinetobacter spp. received little or no attention from 
the health care community; these species were considered low risk bacteria until the 
1970s-1980s, when its clinical significance began to increase (Abrutyn et al., 1978; 
French et al., 1980). This change in the pathogen behavior has been connected to the 
introduction of potent broad-spectrum antibacterial used after complex invasive 
procedures that confined patients to ICUs (Bergogne-Berezin and Towner, 1996). This 
modification has caused an increase in the selection pressure on bacteria like A. 
baumannii, which has resulted in a notable raise in the number of bacteria resistant to the 
most commonly use antibacterials. Since the 1970s, the spread of multidrug-resistant 
(MDR) Acinetobacter strains have become a concern among the medical community 
worldwide (Dijkshoom et al., 2007). 
 A. baumannii  has been linked to a variety of nosocomial infections including 
pneumonia, bacteremia, meningitis, urinary tract infections, as well as skin and soft tissue 
infections (Fournier and Richet, 2006; Dijkshoom et al., 2007). The mortality associated 
with these pathogens is notably high among immune compromised individuals (Jain, 




Canada and United States infected with MDR A. baumannii (Tien et al., 2007). This has 
triggered an increase in the number of nosocomial infections among civilian patients 
exposed to the pathogen in healthcare facilities (Centers for Disease Control and 
Prevention (CDC), 2004; Hujer et al., 2006). Perez et al. (2007) reported the existence of 
a notable increase in community-acquired infections linked to MDR A. baumannii during 
the last decade revealing the severity of the problem and the urgent necessity of finding a 
solution.  
 
1.2. EPIDEMIOLOGY AND ANTIBIOTIC RESISTANCE 
 
Epidemiological studies have reported the presence of this pathogen among a 
variety of surfaces, from human skin to inert elements like bed railing and health care 
equipment (Cisneros et al., 1996; Corbella et al., 1996; Houang et al., 2001; Dent et al., 
2010). Berlau et al (1999) observed that 40% of the 192 healthy volunteers participating 
in their study carried Acinetobacter spp. This pathogen has also been reported among 
body lice obtained from homeless individuals in France (La Scola and Raoult, 2004), and 
blood of patients treated in hospitals tending military personnel injured in Afghanistan and 
Iraq-Kuwait (Centers for Disease Control and Prevention (CDC, 2004). Furthermore,   
epidemiological studies found that Acinetobacter species grew in 17% of fruit and 
vegetables collected from hospital suppliers, from this group 56% of the isolates 
corresponded to A. baumannii (Berlau et al., 1999 a, b). Acinetobacter spp. has been 
recognized for its extraordinary capacity to survive for long periods of time, up to 5 
months, on inanimate elements in health care facilities (Bergogne-Berezin and Towner, 




Dent et al. (2010) described the colonization of a large variety of hospital equipment and 
room paraphernalia by A. baumannii, these observations resulted in a direct correlation 
with the number of colonized and infected patients in these institutions (Dent et al., 2010).  
 Finally, one of the most important factors that have made of A. baumannii a 
significant threat to hospitalized patients is its ability to acquire resistance to clinical 
relevant antimicrobial agents. MDR A. baumannii has become an emergent cause of 
outbreaks worldwide (Juni, 1972; Fournier et al., 2006; Iacono et al., 2008). Several 
researchers have reported a higher number of outbreaks involving resistant A. baumannii 
in comparison with other species of Acinetobacter, like Acinetobacter lwoffii, 
Acinetobacter johnsonii, and Acinetobacter junii, which are sporadically implicated in 
these medical incidents (Dijkshoorn et al., 1996; Jawad et al., 1998; Heinemann et al., 
2000). Infections caused by A. baumannnii have become very difficult to treat due to the 
growing number of MDR strains showing low susceptibility to β-lactams, 
aminoglycosides, fluoroquinolones, and more recently carbapenem (Afzal-Shah et al., 
2001; Valenzuela et al., 2007; Mark et al., 2009).  
Drug resistance in A. baumannii has been attributed to intrinsic mechanisms 
present in Gram-negative species, and to its extraordinary capacity to acquire genetic 
information horizontally by accumulating resistance factors (Magnet et al., 2001; Lopez-
Hernandez et al., 2001; Mammeri et al., 2003; Heritier et al., 2005; Poirel et al., 2010). In 
addition, a number of intrinsic mechanisms have been identified in A. baumannii including 
β–lactam resistance, reduced membrane permeability, drug bypass and presence of 
strong efflux systems, which in concert confer an effective resistance mechanism 
(Magnet et al 2001; Nordmann et al. 2005, Ribera et al 2003; Spence et Towner, 2003; 
Turton et al. 2004; Huys et al. 2005; Mussi et al 2005; Damier-Piolle et al. 2008). Recent 




broad specificity, plays a central role in the innate resistance of Gram-negative bacteria 
(Coyne et al., 2010; Damier-Piolle et al., 2008; Lin et al., 2009). These reports emphasize 
the possibility of using these structures as a potential drug target to develop a more 
effective treatment against MDR bacteria. 
 
1.3. RESISTANCE-NODULATION CELL-DIVISION (RND) EFFLUX PUMPS 
Multidrug efflux pumps belonging to the Resistance-Nodulation cell-Division 
(RND) family has been identified as the most common and important efflux system 
among MDR Gram-negative bacteria (Poole et al., 1993; Ma et al., 1995; Li et al., 2002; 
Lin et al., 2009). Recent data suggests that RND efflux pumps are also important in 
pathogenicity and/or survival of these bacteria in a particular ecological niche. Some of 
the possible roles are cell detoxification by eliminating toxic metabolic by-products from 
the cytoplasm (Helling et al., 2002), host colonization and secretion of virulence factors 
increasing pathogenicity of these strains (Brown et al., 2007; Lin et al., 2005; Hirakata et 
al., 2002), and cell-cell communication which facilitate a coordinated response of the 
bacterial colony (Chan et al., 2007). Even though the natural function of the RND efflux 
pumps in Gram-negative bacteria is a fascinating topic, it is undeniable that their 
contribution to the resistance mechanism is a more urgent matter. 
 Three RND pumps have been characterized in A. baumannii, AdeABC, AdeDE, 
and AdeIJK. AdeIJK contributes to resistance to β-lactams, chloramphenicol, tetracycline, 
erythromycin, lincosamides, fluoroquinolones, fusidic acid, novobiocin, rifampin, 
trimethoprim, acridine, safranin, pyronine, and sodium dodecyl sulphate (Darmier-Piolle 




and is involved in the decrease of the level of susceptibility to drugs including 
fluoroquinolones, tetracyclines, amikacin, chloramphenicol, cefotaxime, erythromycin, 
gentamicin, kanamycin, norfloxacin, netilmicin, ofloxacin, perfloxacin, sparfloxacin, 
tobramycin, trimethoprim, and ethidium bromide, and more recently, tigecycline (Magnet 
et al., 2001; Ruzin et al., 2007; Hornsey et al., 2010). In addition, AdeDE is responsible 
for reduced susceptibility to amikacin, ceftazidime, ciprofloxacin, meropenem, and 
rifampin (Chau et al., 2004; Magnet et al., 2001).  
  
1.4. STRUCTURE OF RND EFFLUX PUMPS 
AcrAB-TolC identified in E. coli is the most thoroughly studied RND efflux pump, 
and its structure is commonly used to explain the general efflux mechanism of RND 
pumps. First reported in 1993 (Ma et al., 1993), this pump has a broad variety of 
substrates including acriflavine, β-lactams, fluoroquinolones, chloramphenicol, bile salts, 
crystal violet, ethidium bromide, fatty acids, macrolides, organic solvents, and SDS (Lin et 
al., 2009; Hornsey et al., 2010; Ruzin et al., 2007; Ma et al., 1993).  
 Studies of AcrAB-TolC efflux pump structure revealed the AcrB protein is 
embedded in the inner membrane, associated with an outer-membrane channel and a 
periplasmic adaptor protein, TolC and AcrA respectively (Fig. 1.1) (Ma et al., 1993). The 
E. coli outer-membrane protein, TolC, has been identified as a trimer of two joined barrel-
like structures that serves as a channel through the outer-membrane during the extrusion 
of the substrates (Koronakis et al., 2000). This protein contains a 12-strand β-barrel 
configuration which forms a 30Å pore, attached to these strands of β-structures there is 




docking domain of AcrB (Murakami et al., 2002). AcrB, which is inserted into the inner 
membrane, has been described as a homotrimer with three-fold rotational symmetry 
(Murakami et al., 2002). This protein is composed of 1,100 amino-acids, and it possesses 
a large periplasmic domain of at least the same size as the transmembrane (TM) domain, 
the last one divided into 12 segments. The top portion of the periplasmic domain of AcrB 
has similar dimensions to the tip of TolC binding domain, supporting the idea of a close 
assembly between AcrB and TolC inside the periplasm (Touze et al., 2004; Koronakis et 
al., 2000; Murakami et al., 2002). The coordinated operation between AcrB and TolC 
appears to be mediated by AcrA, this periplasmic protein has been identified as a 
member of the membrane fusion protein (MFP) family (Tikhonova and Zgurskaya, 2004). 
The AcrA fragment is composed of three domains: β-barrel, lipoyl, and α-helical hairpin. 
According to current research, this last structure possesses extraordinary flexibility, 
relevant characteristic in the coupling mechanism associated with the functionality of the 
efflux pump tripartite structure (Touze et al., 2004; Tikhonova and Zgurskaya, 2004; 
Mikolosko et al., 2006).  
The analysis of the recently available genome sequence of A. baumannii 
ATCC17978 reveals the presence of three other RND complex-encoding operons, 
namely A1S_2304-A1S_2305-A1S_2306, A1S_2817-A1S_2818 and A1S_3219-
A1S_3218-A1S_3217-A1S_3214 in addition to the previously described AdeABC 
(Magnet et al, 2001), AdeIJK (Damier-Piolle et al., 2007), and AdeDE (Chau et al., 2004) 
pumps (Fig. 1.2). Indeed, while some of the recent studies have shown that AdeABC, 
AdeIJK, and AdeDE pumps are expressed extensively in the clinical isolates of A. 
baumannii (Chu et al., 2006; Lin et al., 2009), there are also reports of multidrug resistant 




RND pumps (Lin et al., 2009). These observations suggest that yet uncharacterized 
pumps may be involved in the antibiotic resistance mechanism of these microorganisms. 
 In summary, RND efflux pumps are a great example of adaptation mechanism 
present in Gram-negative bacteria. The knowledge obtained during this study will 
contribute to the understanding of RND efflux pumps, as well as their participation in the 
global mechanism used by this microorganism to overcome adverse conditions in clinical 
setting. Finally, this research will supply additional information to create an appropriate 










Figure 1.1. Structures of the proteins constituting the tripartite AcrAB-TolC efflux 
machinery. TolC (OMP) forms a pore in the outer-membrane which is extended by a 
long periplasmic channel facilitating the compounds extrusion from the cell. AcrA (MFP) 
mediates the contact between AcrB and TolC. AcrB (RND efflux pump) inserted into the 
inner membrane, is responsible for substrate recognition/selection as well as for energy 
transduction. Drug molecules are captured from the periplasm side of the inner 
membrane, then transferred through the periplasmic porter (pore) domain towards the 
funnel of TolC and extruded into the external media (Eswaran et al., 2004) (Reproduced 

























Figure 1.2. Genetic organization of RND complex-encoding operons in the A. 
baumannii ATCC17978 genome. Genes encoding RND pump components are shown 
in shaded block arrows, while genes shown in white block arrows do not show any 





































1.5. RESEARCH AIMS 
 This thesis project was divided in three main objectives: 
 
A. Study the expression of RND efflux pumps in clinical isolates of Acinetobacter 
baumannii from Canadian hospitals. 
 
B. Cloning and characterization of AdeMNO, a novel RND efflux pump of Acinetobacter 
baumannii. 
 


















2.1. BACTERIAL STRAINS, PLASMIDS AND OLIGONUCLEOTIDES 
Plasmids, bacterial strains, and oligonucleotides used in this study are listed in 
Tables 2.1, 2.2, and 2.3 respectively. The clinical isolates of A. baumannii used in this 
study were obtained from Canadian Hospitals all over Canada and were provided by Dr. 
George Zhanel, University of Manitoba, Canada. A. baumannii ATCC19606 was used as 
the reference strain. 
 
2.2. MEDIA AND GROWTH CONDITIONS  
All bacterial strains were routinely grown in Luria-Bertani (LB) medium (Bioshop 
Canada Inc, Burlington, ON, Canada) and incubated at 37˚C. The following 
concentrations of antibiotics were used in order to maintain respective plasmids, for 
selection or counterselection of E. coli strains, 100 μg/mL ampicillin (Ap) (Bioshop, 
Burlington, ON, Canada), 10 μg/mL gentamycin (Gm) (Bioshop, Burlington, ON, Canada), 
15 ug/mL streptomycin (Sigma Aldrich Co., St Louis, MO, USA). Concentrations of 
antibiotics used for Pseudomonas aeruginosa and A. baumannii are listed in the following 
sections. LB media supplemented with 5% sucrose (Bioshop, Burlington, ON, Canada) 
was used for curing plasmids containing the sacB counterselection marker. Mueller-
Hinton broth (BD-Canada, Mississauga, ON, Canada) was used in order to perform the 
antibiotic susceptibility assays. Induction of gene expression was achieved by 
supplementing the media with 1mM isopropyl-β-D-thiogalactopyranoside (IPTG) 





2.3. FREEZER STOCKS 
Freezer stocks were prepared by mixing 1.5 mL of saturated overnight culture with 
sterile 80% glycerol solution to a final concentration of 15% glycerol. The cryovials were 
immediately placed into the -80˚C freezer for storage. 
  
2.4. DNA EXTRACTION 
Genomic DNA was extracted using the DNeasy Kit from Qiagen (Qiagen, 
Mississauga, ON, Canada) according to manufacturer’s instruction. Cells from 1.5 mL of 
overnight culture were harvested and directly lysed by incubating with proteinase K at 
56˚C for 10 min, buffer containing 51% of 96-100% alcohol was added and the mix was 
transferred to a silica base column. The column was washed twice with ethanol solution 
and the DNA was extracted from the column using 20 to 50 µL of elution buffer. 
Plasmid DNA was extracted using EZ-10 Spin Column Plasmid DNA Miniprep Kit 
from BioBasic (BioBasic Inc., Markham, ON, Canada) by following the manufacturer’s 
instructions. The DNA concentration was measured using Eppendorf BioPhotometer 
Model AG (Barkhausenweg, Hamburg, Germany) and the samples were stored either at 
4˚C or -20˚C.  
 
2.5. EXTRACTION OF DNA FRAGMENTS FROM AGAROSE GELS 
The EZ-10 Spin Column Gel Extraction Kit from BioBasic (Bio Basic Inc., 
Markham, ON, Canada) was used to purify DNA from agarose gels following the 




Buffer by incubating at 56˚C for 10 min. The mix was transferred to a column containing a 
silica membrane and washed twice with ethanol solution. The DNA was extracted using 
between 25 to 50 μL of Elution Buffer. Samples were stored at -20˚C until use. 
  
2.6. RNA EXTRACTION AND cDNA SYNTHESIS 
RNA extractions were performed using the RNeasy Kit (Qiagen, Mississauga, ON, 
Canada). Overnight cultures grown in LB was subcultured in fresh LB, 1 mL of late log 
phase (A600nm ≈0.8) culture was harvested, and the pellet was frozen at -80ºC for 15 
min to facilitate cell lysis.  RNA extraction was carried out following the manufacturer’s 
instructions, 1 x 109 bacteria were disrupted using a guanidine-thiocyanate–containing 
lysis buffer. After adding ethanol to the mix, the samples were loaded into the RNeasy 
Mini Spin Column. Total RNA binded to the RNeasy silica membrane, and impurities 
were washed away using alcohol base solution. Total RNA was extracted from the spin 
column using RNase-free water. Synthesis of the cDNA was performed using the 
QuantiTect Reverse Transcription Kit (Qiagen, Mississauga, ON, Canada) according to 
manufacturer’s instructions. Briefly, RNA samples were treated with gDNA Wipe-out 
buffer for 10 minutes to eliminate any trace of genomic DNA. After DNA elimination, 
cDNA was obtained from 0.5 μg of total RNA using Reverse Transcriptase.  
 
2.7. DNA RESTRICTION ENZYME DIGESTION AND LIGATION 
Restriction enzymes were used to confirm the identity of the plasmids, as well as 




instructions. Ligations were accomplished using T4 DNA ligase (New England Biolabs 
Ltd., Pickering, ON, Canada) using varying molar ratios of the insert and vector. Ligation 
reactions were incubated for 1 hr at 37˚C or overnight at room temperature. Blunt end 
ligation reactions were incubated overnight in a 25˚C water bath.  
 
2.8. POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION 
Plasmids, genomic DNA, and cDNA prepared as described above were used as 
template for PCR amplification. Occasionally the template for PCR was also prepared 
from cells taken from a culture plate. Cells scraped from a bacterial colony using a sterile 
toothpick were suspended in 20 μL of sterile millipore water and the suspension boiled for 
10 min. Cell debris was removed by microcentrifugation at 13,300 rpm for 2 min; 2 μL of 
the supernatant were used as template in a 25 μL PCR reaction.  
Depending on the reaction conditions and the size of the product, PCR reactions 
were performed using a variety of polymerases. Taq DNA polymerase (New England 
Biolabs, Pickering, ON, Canada) was used routinely for the screening procedures, Bio-X-
Act (Bioline, Randolf, MA, USA) was successfully used in the amplification of adeMNO 
operon, Phire (Finnzymes, Espoo, Finland) was used in the final stage of the Splicing by 
Overlapping Extension PCR described bellow and Go Taq DNA polymerase (Promega, 
Madison, WI, USA) was regularly used in the amplification of any other template. All 
these polymerases were utilized following the manufacturer’s instructions. 
 DNA amplification was carried out for either 25 or 30 cycles using 50 ng of 
genomic DNA from A. baumannii isolates or 1μL of cDNA obtained from 0.5 μg of total 




calculated using the following formula: 4(G+C) + 2 (A+T) – 5. For RT-PCR reactions, 
primers were designed using the OligoPerfect primer designing tool from Invitrogen 
(http://www.invitrogen.com) to anneal to the RND component-encoding gene of each 
operon. Ribosomal 23S rRNA gene was used as the housekeeping control, while A. 
baumannii ATCC19606 was used as the reference strain. 
 
2.9. SPLICING BY OVERLAP EXTENSION (SOEing) PCR 
The splicing Overlap Extension (SOEing) reaction was used to generate deletion 
fragments for adeMNO and adeL with the purpose of creating gene knock-outs using 
Choi and Schweizer method (Choi and Schweizer, 2005) (Fig 2.1.). This method consists 
of two rounds of PCR reaction. The first round involved amplifying the gentamycin-
resistant (Gmr) marker and the flanking regions of the target gene/operon using Go Taq 
DNA polymerase (Promega, Madison, WI, USA). Gmr marker was obtained by PCR 
amplification of the aacC1 gene from 50 ng of the plasmid pPS856 (Hoang et al, 1998). 
Flanking regions of the target gene/operon were amplified using the genomic DNA of A. 
baumannii ATCC19606 and adding engineered overlapping regions to the aacC1 gene in 
each of the fragments. The sequences of the primers used in this work are described in 
Table 2.3. The resulting fragments Gmr (1,053 bp), the 5’- and 3’-ends of the target 
gene/operon were purified from agarose gel using the method described in section 2.5. 
and its concentration determined spectrophotometrically (Absorbance260 nm) using the 
Eppendorf BioPhotometer Model AG. 
Forty nanograms of each of the three fragments were used as template for the 




cycles (annealing temperature, 55˚C), following which, the forward and reverse primers of 
3’- and 5’-ends of the target gene were added and the reaction continued under the same 
conditions for 35 cycles. Phire (Finnzymes, Espoo, Finland) Taq DNA polymerase was 
used for SOEing reactions following the manufacturer’s instructions. The resulting PCR 
product was cloned into the pUC18 cloning vector, followed by sub-cloning into pEX-Km5 
suicide plasmid for further applications. The creation of ΔadeMNO::Gm-FRT fragment is 
illustrated in the Fig. 2.1.  
 
2.10. PREPARATION OF COMPETENT CELLS AND TRANSFORMATION 
Transformations were performed using chemically prepared competent cell 
(Samshcokbrook and Russell, 2001) or commercial competent cells E. coli JM109 
(Promega, Madison, WI, USA). Transformations were performed using the heat shock 
method following standard laboratory protocols (Sambrook and Russell, 2001).  
Transformation reactions were incubated at 37˚C for 1 hr with shaking and plated on LB 
agar selective media containing appropriate concentration of antibiotic(s). For blue and 
white colony screening, the transformants were plated on LB agar supplemented with 40 
μg/mL X-gal, 1 mM IPTG and the appropriate antibiotic. Competent cells JM109 
purchased from commercial suppliers were used according to manufacturer’s 
instructions. Briefly, 100 µL cells were retrieved from -70˚ C freezer and thawed on ice for 
5 min. Fifty to one hundred nanograms of the plasmid were added into the cell 
suspension and the mix incubated for 20 min on ice. Cell were then heat shocked at 42˚C 




of room temperature LB media. After incubating the transformed cells at 37 ˚C for 1 hr, 
they were plated into the appropriated selection media and incubate at 37˚C overnight. 
  
2.11. PREPARATION OF ELECTROCOMPETENT CELLS AND TRANSFORMATION 
BY ELECTROPORATION 
Transformation of P. aeruginosa strains was performed using the electroporation 
method previously described by Choi and Schweizer (2005). Electrocompetent cells were 
obtained by equally distributing 6 mL of overnight culture in 4 microcentrifuge tubes 
followed by centrifugation at 13,300 rpm for 2 min. The pellets were pooled and washed 
twice using 1 mL of 300 mM sucrose solution. After the second wash, the supernatant 
was discarded and the cells resuspended in a total of 100 μL of 300 mM sucrose solution.  
 Electroporation was performed by adding 50-250 ng of DNA to the cell 
suspension. The mix was transferred to a 2 mm electroporation cuvette and an electrical 
pulse was applied at 2.5 KV with default settings of 10 μF for 5 sec using an Eppendorf 
electroporator Model 2510 (Eppendorf North America, Inc., Westbury, N.Y., USA ). 
Immediately following the pulse 1 mL of room temperature LB media was added to the 
cuvette, the cells were transfered to a microcentrifuge tube and incubated at 37˚C for 2 
hr. One hundred microliters of the culture was plated on LB agar supplemented with the 
appropriate antibiotic. The remaining cells were harvested by centrifugation, resuspended 
in 100 μL LB broth and plated on the same selective media. Plates were incubated at 











Figure 2.1. Schematic illustration of mutant fragment generation by SOEing 
reaction for adeMNO operon. A PCR was performed to amplify 307 bp of the 5’-end of 
the adeM gene, designed in the figure as adeM’, and 349bp of the 3’-end of the adeO 
gene, designed as adeO’. These fragments were mixed with Gmr cassette (aacC1) to 
obtain the adeMNO deletion fragment. Quality of the PCR products was accessed on a 
0.8% agarose gel (A). These purified products which contained aacC1 overlapping 
sequences (orange boxes) were then assembled by SOEing reaction using PCR1 and 
PCR2 cycles. PCR1 reactions were prepared using equal amounts (40 ng) of each 
fragment in the absence of the primers, the run was paused after 5 cycles and primers 
were added to the reaction. Immediately after, PCR2 was run for 35 cycles to allow the 
amplification of the SOEing product. The presence of ΔadeMNO::Gm-FRT gene deletion 
fragment obtained from PCR2 was visualized on a 0.8% agarose gel prior to cloning, 































2.12. INSERTION OF the adeMNO OPERON IN SINGLE COPY IN P. aeruginosa  
A single copy insertion of adeMNO operon into P. aeruginosa PAO750, PA0200 
and PA0397, was perfomed as described by Kumar et al. (2006). The insertion was 
obtained by electroporating P. aeruginosa with plasmids pPLS018 and pTNS2 that 
provided transposes A, B, C, and D in trans.  
Electroporation mix was plated on LB-agar Gm30 plates and incubated at 37oC 
overnight. Gentamicin resistant colonies were screened for the insertion of the mini-Tn7 
element by PCR using primers Tn7R and PglmSDN1. The primer Tn7R binds to the 
miniTn7 plasmid sequence, while PglmSDN1 binds to the glmS gene generating an 
amplicon of 240 bp. Insertion was also confirmed by the presence of aacC1 gene. 
Screening PCR was performed using internal primers for the aacC1 gene, Gm_R and 
Gm_F;  together they amplified a product of 548 bp. The P. aeruginosa PAO750 
derivative that contained the marked insertions of adeMNO operon was named P. 
aeruginosa PA006.   
Removal of the Gmr marker was achieved by using the Flp-FRT system described 
by Choi and Schweizer (Choi and Schweizer, 2006).  Briefly, P. aeruginosa PA006 was 
electroporated with pFLP2 (Kumar et al, 2006) as described above in section 2.11 and 
cells plated on LB agar media supplemented with 200 μg/mL carbenicillin (Cb200). 
Screening was performed by patching colonies on Cb200 and Gm30, selecting those that 
grew on Cb but not on Gm. The plasmid pFLP2 was cured by streaking the patches on 
LB-agar supplemented with 10% sucrose.  Resulting colonies were patched on LB-10% 
sucrose, LB-Cb200 and LB-Gm30 plates to confirm the loss of pFLP2 plasmid and 
reconfirm the absence of aacC1 gene. Patches that were sucrose resistant but Cb- and 




described above and also re-tested for the insertion of the mini-Tn7 element.  The 
resulting strain was named as P. aeruginosa PA008. 
 
2.13. ANTIBIOTIC SUSCEPTIBILITY TESTING 
Antibiotic susceptibility testing for the bacterial strains in this study was performed 
using the Vitek II system (BioMerieux Inc, Montreal, Canada), two fold serial dilution test 
and the disk diffusion susceptibility assays. All tests were carried out following the 
recommendations by Clinical and Laboratory Standards Institute (CLSI) (NCCLS 2010). 
Muller-Hinton broth was used for the susceptibility assays. Induction of the efflux pump-
encoding operon was achieved by supplementing the growth medium with 1mM IPTG. 
Bacterial growth was examined after 18 hrs of incubation at 37°C. Antimicrobial 
resistance results were interpreted according to CLSI guidelines (NCCLS 2010). 
Antibiotic tested were chosen according to reference and availability.  
 
2.14. FOUR PARENTAL MATING 
Four parental mating was performed following a method previously described 
(Goldberg and Ohman, 1984) in order to transfer mini-Tn7 elements in A. baumannii 
strains. This involved transfer of two plasmids required for achieving transposition, 
namely the mobilizable mini-Tn7 suicide delivery plasmid (E. coli strain with the mini-Tn7 
suicide delivery plasmid) and the mobilizable transposes-encoding plasmid (E. coli strain 
containing the helper plasmid pTNS2) to the recipient strain (A. baumannii ATCC19606) 




encoding the mobilization helper functions. One hundred millilitres of the overnight 
cultures of the donor, helpers and recipient stains grown in LB broth containing 
appropriate antibiotic(s) (ampicillin for the E. coli strain containing the mini-Tn7 delivery 
vector and helper plasmid containing pTNS2, kanamycin for the E. coli strain containing 
pRK2013 and no antibiotic for A. baumannii recipient strain) were mixed into 1mL of LB 
broth followed by microcentrifugation at 13,300 rpm for 1 min. The bacterial pellet was 
washed twice with 1mL of LB and carefully suspended into 50 μL of fresh LB broth. 
Bacterial suspension was spot plated on a pre-dried LB agar plate and incubated 
overnight at 37˚C. Following the incubation, the bacterial cells were washed with 1mL of 
saline (0.85% NaCl), 100 μL of the suspension was plated on LB agar plate 
supplemented with Gm (100 μg/mL) for the selection of A. baumannii transformants 
containing the mini-Tn7 insertion and streptomycin (15 μg/mL) for the counterselection of 
E. coli strains. The remaining cells were then centrifuged at 13,300 rpm for 2 min, the 
supernatant was eliminated, and the pellet resuspended in 100 μL of LB broth. The cells 
were then plated on a second LB agar plate supplemented with the above antibiotics. The 
plates were incubated at 37˚C overnight and the colonies screened for insertion using 
PCR. 
Screening of the mini-Tn7 insertion in A. baumannii cells was performed using 
single colony PCR by determining the presence of aacC1 gene (internal primers Gm_R 
and Gm_F) and mini-Tn7 insertion downstream from A. baumannii glmS gene (Kumar et 
al, 2010) (primers Tn7R in conjunction with glmS primer PglmSDN1). The conditions for 
the run were as follow: initial denaturation at 95˚C for 5 min; 95˚C for 30 sec, 55˚C for 30 
sec, and elongation at 72˚C for 30 sec. Fragments obtained in this amplification were 548 





2.15. N-ACYL HOMOSERINE LACTONE (AHL) BIOASSAY 
AHL bioassays were performed using the method described by Andersen et al. 
(Andersen et al., 2001) with some modifications. Overnight cultures of E. coli MT102 
harbouring pJBA132 (grown at 30˚C) and the P. aeruginosa strain containing the 
adeMNO operon (grown at 37˚C) were equilibrated in saline using the 0.5 McFarland 
turbidity standard (~108 cells/mL). Five microliters of each equilibrated suspension was 
streaked close to each other in the form of a ‘T’ on a LB-agar plate supplemented with- or 
-without 1 mM IPTG. Plates were incubated at 30˚C, and examined for green 
fluorescence every 24 hrs for 4 days.  
 
2.16. SEQUENCING AND SEQUENCE ANALYSIS 
DNA sequencing was carried out at the Genome Quebec facility at McGill 
University, Montreal, QC. The sequence analysis was performed using Basic Local 
Alignment Search Tool (BLAST), Conserved Domains Database (CDD) and Gene 





Table 2.1. List of plasmids used in the study 




Apr, TA PCR cloning vector 
 
Promega 
pTNS2 Apr; R6K replicon, helper plasmid 






pFLP2 Cbr; source of Flp recombinase; curable 
by sucrose counterselection 
(Hoang et al., 
1998) 
 
pPLS1464 Apr Gmr; mini-Tn7 expression vector 
containing lacIq and tac promoter 













Apr, pGEM-T-easy containing the adeL 





pPLS013 Apr, pGEM-T-easy containing the adeL 





obtained by PCR amplification 
 
Apr, pGEM-T-easy containing the 
adeMNO operon of A. baumannii 






















containing the adeMNO operon of A. 
baumannii ATCC19606 
 
pEX-Km5 contains the sacB gene that can 
be used as counter-selectable marker. 





Apr, pGEM-T-easy containing the 


































Apr, pGEM-T-easy containing the 
adeMNO promoter region of A. baumannii 
63487 
 
Apr, pGEM-T-easy adeL from A. 
baumannii  64797 strain 
 
Apr, pGEM-T-easy adeL from A. 
baumannii  63487 strain 
 
Apr, Gmr, pUC18 ΔadeMNO::Gm-FRT 
 















pPLS041 Kmr, Gmr, pEXKm5 ΔadeMNO::Gm-FRT 



















Table 2.2. List of strains used in the study 
A. baumannii 
strains 





A. baumannii  
(Bouvet and Grimont deposited as 
Bacterium anitratum Schaub and Hauber) 
 





(isolated from respiratory system of a 75 
years old patient from Winnipeg)  
 





(isolated from respiratory system of a 1 
year old patient from Winnipeg) 
 




Clinical isolate  
(isolated from respiratory system of a 64 
years old patient from Vancouver) 







(isolated from respiratory system of a 33 
years old patient from Vancouver) 
 






(isolated from blood of a 30 years old 
patient from Hamilton) 
 





(isolated from respiratory system of a 26 
years old patient from Hamilton) 







(isolated from respiratory system of a 75 
years old patient from Vancouver) 
 





(isolated from respiratory system of a 54 
years old patient from Winnipeg) 







(isolated from respiratory system of a 4 
year old patient from Victoria) 
 
 








(isolated from respiratory system of a 20 
years old patient from Vancouver) 
 





(isolated from blood of a 25 years old 
patient from Montreal) 
(Zhanel et al., 
2008) 
 
A. baumannii  
AB016 
 






A. baumannii  
AB017 
 























PAO01: Δ(mexAB-oprM), Δ(mexCD-oprJ), 






























Gmr, PAO200 with chromosomally 
integrated pUC18-mini-Tn7T-Gm-LAC 






























































PA033 without Gm marker 
 
    
This study 
 
E. coli strains Relevant characteristics Reference 
 
E. coli JM109 
 
recA1, endA1, gyrA96, thi,hsdR17(rK-, mK+), 
relA1,supE44, Δ(lac-proAB), [F’,traD36, 
proAB, lacIqZΔM15] 
 
       
 Promega 
E. coli GBE180 F- Φ80d lacZΔM15 Δ(lacZYA-argF) U169 
recA1endA1 hsdR17 (rk-, mk+) phoA 
supE44 λ- thi-1 gyrA96 relA1 pcnB 
 
(Pierais et al., 
1999) 




F- Φ80d lacZΔM15 Δ(lacZYA-argF) U169 
deoR recA1endA1 hsdR17 (rk-, mk+) phoA 

















adeB_R_RT 5’-AATACTGCCGCCAATACCAG-3’ This study 
adeB_F_RT 5’-GGATTATGGCGACTGAAGGA-3’ This study 
 adeN 
Ab-A1S-2305-RTr 5’-ATCGCGTAGTCACCAGAACC-3’ This study 
Ab-A1S-2305-RTf 5’-CGTAACTATGCGGTGCTCAA-3’ This study 
adeE 
adeE_R_RT 5’-GCCTGCGTTATTTCTACCC-3 This study 
adeE_F_RT 5’-GAAACAGAGCGGGTTGGTAA-3’ This study 
A1S_2818 
2818_R_RT 5’-AATTGAGCCAAGCTCATGCT-3’ This study 
2817_R4 5’-TATTGATTTCCCATTCGTAG-3’ This study 
 adeJ 
adeJ_F1_RT 5’-CATCGGCTGAAACAGTTGAA-3’ This study 
adeJ_R1_RT 5’-GCCTGACCATTACCAGCACT-3’ This study 
A1S_3217 
3219_R_RT 5’-GTGACTTGGGAAAGCCCATA-3’ This study 
3219_F_RT 5’-ACCGCTTTAGAGGTCGAACA-3’ This study 
23S rRNA 
23S_R_RT 5’-GGGAGAACCAGCTATCACCA-3’ This study 






























(Choi et al., 
2005) 



































aacC1 gene Gm_F 5’-TGGAGCAGCAACGATGTTAC-3’ (Choi and 
Schweizer,2005) 
 


























































* Restriction site indicated by underlined bases and restriction enzyme indicate in 
parentheses, the base modifications introduced to generate the new restriction sites are 































A. EXPRESSION OF RND EFFLUX PUMPS IN CLINICAL ISOLATES OF 











3. A.i. DETECTION OF RND COMPONENT-ENCODING GENES IN CLINICAL 
ISOLATES OF Acinetobacter baumannii 
PCR was used to determine the presence of RND component-encoding genes in 
eleven A. baumannii isolates using primers specific to the individual RND pump genes. 
All of the clinical isolates contained at least three different RND component-encoding 
genes (Table 3.1). Two genes, adeJ from the adeIJK operon, and adeN from the 
adeMNO operon, were present in all isolates (Figs. 3.1.D.i and 3.1.E.i). The adeB gene of 
the adeABC operon was found in seven (Fig.3.1.B.i), adeE of the adeDE operon in 10 
(Fig. 3.1.C.i), A1S_2818 of the A1S_2817-A1S_2818 operon in six of the 11 isolates 
tested (Fig. 3.1.F.i), while A1S_3217 of the A1S_3219-A1S_3218-A1S_3217-A1S_3214 
operon was found in only one isolate (Fig. 3.1.G.i). The reference strain ATCC19606 was 
found to harbour the adeB, adeJ, adeN, A1S_2818 and A1S_3217 genes.  
 
3.A.ii. EXPRESSION OF RND PUMP-ENCODING GENES  
Expression of efflux pumps was determined by end-point RT-PCR using cDNA 
samples synthesized from RNA of different A. baumannii strains as templates. Results of 
RT-PCR reactions are summarized in Table 3.1. The genes adeB and adeJ were 
detected in cDNA samples after 25 PCR cycles, while all other RND pump-encoding 
genes, namely adeE, A1S_2818, adeN, and A1S_3217, were detected after 30 cycles. In 
the cases of adeE and adeN, they were the most prominently expressed RND 
component-encoding genes in the clinical isolates, with adeE being expressed in eight  of 
the 10 isolates (80%) and adeN in eight of the 11 isolates (72%) that harboured the 




seven (57%) and adeJ was expressed in four out of 11 isolates (36%) that harboured the 
respective genes (Figs. 3.1.B and 3.1.D). A1S_2818 was expressed in five out of six 
strains (83%) harbouring the gene (Fig. 3.1.F), while A1S_1 3217 was expressed in the 
only strain that contained the gene (Fig. 3.1.G). Control strain A. baumannii ATCC 19606, 
which sequence has been published, showed expression of only three of the five RND 
genes present in its genome, namely adeB, adeJ and A1S_3217, A. baumannii 64130, 
isolated from a 30 year old patient in Hamilton, ON, was found to express the highest 
number of efflux pumps among all isolates, expressing all but the adeE gene, even 
though this gene was found in this strain. A. baumannii 59960 and A. baumannii 64397, 
both isolated from Vancouver, BC, were found to express the adeE gene only. The 







Table 3.1. Summary of PCR results for the detection of RND pump-encoding genes 
and their expression in A. baumannii isolates. 
 Detection of RND-pump-encoding gene / detection of mRNA 
Strain adeB adeE adeJ adeN A1S_2818 A1S_3217 Total 
A. baumannii 63169 + / + + / + +/ - + / + + / - - / - 5/3 
A. baumannii 58352 - / - + / + +/ - + / + + / + - / - 4/3 
A. baumannii 59960 + / - + / + +/ - + / - - / - - / - 4/1 
A. baumannii 59973 - / - + / + +/ - + / + + / + - / - 4/3 
A. baumannii 64130 + / + + / - +/ + + / + + / + + / + 6/5 
A. baumannii 64153 - / - + / - +/ + + / + + / + - / - 4/3 
A. baumannii 64797 + / - + / + +/ - + / - - / - - / - 4/1 
A. baumannii 63487 + / + + / + +/ - + / + - / - - / - 4/3 
A. baumannii 65239 - / - + / + +/ + + / + - / - - / - 3/3 
A. baumannii 66310 + / + + / + +/ - + / - - / - - / - 4/2 
A. baumannii 66985 + / - - / - +/ + + / + + / + - / - 4/3 
A. baumannii 
ATCC19606 
+ / + - / - +/ + + / - + / - + / + 5/3 
Total 8/5 10/8 12/5 12/8 7/5 2/2  
+, positive detection and/or expression of the gene  





 Figure 3.1. Analysis of the presence and expression of adeB (B), adeE (C), adeJ 
(D), AdeN (E), A1S_2818 (F), and A1S_3217 (G) RND-pump encoding genes in A. 
baumannii isolates. 1, A. baumannii 63169; 2, A. baumannii 58352; 3, A. baumannii 
59960; 4, A. baumannii 59973; 5, A. baumannii 64130; 6. A. baumannii 64153; 7, A. 
baumannii 64797; 8, A. baumannii 63487; 9, A. baumannii 65239; 10, A. baumannii 
66310; 11, A. baumannii 66985; 12, A. baumannii ATCC19606; M, 100 bp molecular 
weight marker. PCR was performed using genomic DNA (i) and cDNA as template. 
Amplification of cDNA was performed for 25 cycles (ii) and 30 cycles (iii). 23S rRNA (A) 
was used as the housekeeping control gene and amplified using the cDNA preparations 



















A. 23S rRNA 
B. adeB C. adeE 






















3.B.i. IDENTIFICATION AND CLONING OF adeMNO OPERON 
The adeMNO operon was identified from the genome sequence of A. baumannii 
ATCC17978. This pump was named AdeMNO, where AdeM is the membrane fusion 
(MF) protein; AdeN is the RND protein, while AdeO is the outer-membrane (OM) protein. 
Fig 3.2. shows the procedure through which the entire adeMNO operon, including 25 bp 
upstream of the adeM and 28 bp downstream of the adeO gene, was cloned into pUC18-
miniTn7T-Gm-LAC vector. This plasmid allowed the insertion of a single copy of adeMNO 
operon into a surrogate P. aeruginosa strain using electroporation procedure as 
described in Fig.3.3. The resulting P. aeruginosa strain was named PA008 and was used 



















Figure 3.2. Identification and cloning of adeMNO operon. The adeMNO operon was 
identified from the genome sequence of A. baumannii ATCC17978. This operon contains 
the gene encoding the MFP (adeM, 1214 bp), RND protein (adeN, 3176 bp), and the 
OMP (adeO, 1406 bp). PCR was used to amplify the entire adeMNO operon including 25 
bp upstream of the adeM and 28 bp downstream of the adeO gene. PCR product was 
cloned in vector pGEM-T-easy obtaining the plasmid pPLS017 and then subcloned into 
the pUC18T-mini-Tn7-Gm-LAC to yield the plasmid pPLS018. Abbreviation: bla, beta-
lactamase gene conferred beta-lactams resistance (Apr); FRT, Flp recombinase target; 
pTNS2, T7 transposes expression vector; pFLP2, Flp S. cerevisiae recombinase 
expression vector; oriT, RK2-derived origin for conjugal plasmid transfer; lacIq, gene 
encodes the repressor protein; Ptac, strong hybrid promoter composed of the -35 region 


















Figure 3.3. Insertion of adeMNO operon in single copy in the surrogate P. 
aeruginosa strain to obtain PA008. Insertion of the adeMNO operon in the surrogate P. 
aeruginosa strain PAO750 in single copy was carried out by using the method previously 
described (Kumar et al. 2006). Briefly, competent P. aeruginosa cells were prepared 
using a previously described method (Choi et al., 2006) and electroporated with 50 ng 
each of pPLS008 and the helper plasmid pTNS2 (Choi et al., 2005). Transformants were 
selected on LB agar supplemented with Gm (30 μg/mL). Abbreviation: aacC1, gene  
encode for gentamycin acetyltransferase-3-1 which  provide gentamycin resistance; bla, 
beta-lactamase gene provide beta-lactams resistance (Apr); FRT, Flp recombinase 
target; glmS, D-fructose-6-phosphate aminotransferase; pTNS2, T7 transposes 
expression vector; pFLP2, Flp S. cerevisiae recombinase expression vector; oriT, RK2-
derived origin for conjugal plasmid transfer; lacIq, gene encode the repressor protein; 
Ptac, strong hybrid promoter composed of the -35 region of the trp promoter and the -10 
















3.B.ii.  IDENTIFICATION OF THE SUBSTRATES OF AdeMNO PUMP 
The antibiotic susceptibility testing performed using Vitek 2 system indicated an 
increase in resistance of PA008 to trimethoprim/sulfamethoxazole and imipenem under 
inducing conditions (Table 3.2.). In addition the MIC test indicated that the induction of 
the expression of adeMNO pump resulted in 16- and 4-fold increase in the resistance to 
chloramphenicol and trimethoprim, respectively, in PA008. In addition, the MIC for 
clindamycin increased by 32-fold. No significant difference was observed for the 
susceptibilities to ethidium bromide, gentamicin, tobramycin, imipenem, levofloxacin, 
ciprofloxacin, and cefotaxime (Table 3.3.). P. aeruginosa PA034 was obtained by using 
the procedure highlight in Fig. 3.3., this strain containing a single insertion of the miniTn7 











Table 3.2.  Antibiotic susceptibility P. aeruginosa PA008 obtained in a Vitek2 





PA008 + IPTG 
(µg/mL) 
Ampicillin >32 >32 
Piperacillin/Tazobactam <4 <4 
Cefazolin >64 >64 
Cefoxitin >64 >64 
Cefotaxime 32 32 
Ceftazidime <1 <1 
Cefepime <1 <1 
Imipenem <1 2 
Amikacin <2 <2 
Gentamicin <1 <1 
Tobramycin <1 <1 
Ciprofloxacin <0.25 <0.25 
Levofloxacin <0.12 <0.12 
Tigecycline <0.5 <0.5 
Nitrofurantoin 128 128 
Trimethoprim/Sulfamethoxazole <20 40 
Samples were prepared according to CLSI guidelines (NCCLS 2010), and induction 
testing was performed supplementing the samples with 1mM IPTG. Antibiotic in bold 





Table 3.3.  Antibiotic susceptibilities of P. aeruginosa PA008 expressing the 
AdeMNO pump of A. baumannii and PA034 P. aeruginosa control strain.  
 
Antibiotic MIC (μg/mL) measured by broth microdilution method 
 PA008 PA008 + IPTG PA034 PA034+IPTG 
Ciprofloxacin 0.125 0.125 ND ND 
Chloramphenicol 0.5 8 1 1 
Trimethoprim 16 64 1 2 
Gentamycin 1 1 ND ND 
Clindamycin 16 512 8 8 
Ethidium Bromide 64 64 ND ND 
 Zone of inhibition (mm) measured by  
disk diffusion method 
Tobramycin 9.50+0.58 10.50+0.58 9.00+0 9.00+0 
Levofloxacin 17.50+0.58 16.00+0 17.00+0 16.00+0 
Imipenem 10.00+0 10.75+0.50 ND ND 
Nalidixic Acid 12.00+0 12.00+0 ND ND 
Cefotaxime 13.00+0 13.00+0 7.00+0 8.00+0 
Susceptibilities were measured using the two-fold microdilution and the disc diffusion 
methods, all the tests were performed in triplicates. Antibiotics that were identified as 
substrates for AdeMNO efflux pump were listed in bold. The zones of inhibition 
measurements in this table were expressed as average+ SD. Results were 




3.B.iii. N-ACYL HOMOSERINE LACTONE (AHL) BIOASSAY 
The study also investigated the efflux of non-antibiotic compounds by AdeMNO.  
The induction of the expression of adeMNO operon in P. aeruginosa PA008 resulted in 
increased fluorescence of E. coli MT102 harbouring the plasmid pJBA132 indicating 
increased secretion of AHL by P. aeruginosa strain upon induction of the adeMNO 
operon (Fig. 3.4.).  In the case of the reference culture, wild type PA01 and parental 
strain PAO750, both strains showed secretion of the AHL molecule (Fig. 3.4.C. and D. 
respectively). 
 
3.B.iv. CONSTRUCTION OF adeMNO GENE DELETION FRAGMENT  
The adeMNO gene deletion fragment shown in Fig. 2.1., was constructed with the 
purpose of studying the effect of the disruption of the adeMNO operon in A. baumannii 
and confirm the results obtained in the P. aeruginosa strain PA008. The resulting 
fragment ΔadeMNO::Gm-FRT, which carried Gmr selective marker, was first cloned into 
pUC18 plasmid pre-digested with SmaI as a storage plasmid. The resulting plasmid was 
named pPLS035, and its identity was confirmed by PCR using primers Ab_A1S_2304-
SpF and Ab_A1S_2306-KpR, which amplified a 1.7 Kb fragment as seen in Fig. 3.5.B. 
Screening was also performed by restriction enzyme using EcoRV and Xbal, as seen in 
Fig. 3.5.C. and D respectively. The plasmid contains only one restriction site for EcoRV, 
and the product of this digestion was a 4395 bp fragment, as seen in Fig 3.5.C. ln the 
case of Xbal, there are five restriction sites in the resulting plasmid, the size of the 
fragments expected are 3070, 901, 360 and 67 bp. as seen in Fig 3.5.D. (the smallest 




The product obtained from the SOEing reaction shown in Fig. 2.1. was ligated into 
pEX-Km5 plasmid pre-digested with SmaI, obtaining the plasmid pPLS041. The 
confirmation of the identity of the suicide vector containing the ΔadeMNO::Gm-FRT was 





















Figure 3.4. Bioassay for AHL secretion. E. coli strain harbouring the reporter plasmid 
pJBA132 with the gfp gene was monitored for green fluorescence in the presence of P. 
aeruginosa PA008 in the absence (A) and presence of 1mM of IPTG (B), wild type PA01 


























Figure 3.5. Construction of pPLS035 containing adeMNO::Gm-FRT deletion 
fragment. PCR was used to detect the presence of aacC1 gene and ΔadeMNO::Gm-
FRT fragment. Detection of aacC1 gene took place using primers GmFRT-Dn and 
GmFRT-UP, and the resulting amplicon was 1053 bp. Restriction digestions with EcoRV 
and Xbal were performed to confirm the identity of the plasmid. Abbreviations: bla, beta-
lactamase gene conferred beta-lactams resistance (Apr); FRT, Flp recombinase target; 
aacC1, gentamycin acetyltransferase-3-1, the gene conferring gentamycin resistance. 




























Figure 3.6. Construction of the pPLS041 suicide plasmid containing adeMNO gene 
deletion fragment.  Verification of the plasmid composition was done by restriction 
digestion using SpeI/EcoRV and SpeI/KpnI. For the SpeI/EcoRV digestion four fragments 
were expected of 4718, 2470, 1140, 931 and 231bp sizes as seen in Fig. 3.6.C. In the 
case of SpeI/KpnI digestion, the size of the fragments expected were 2664, 2658, 1698, 
1297 and 1173 bp as seen in Fig. 3.6.D. Abbreviations: sacB, Bacillus subtilis 
levansucrase counter selection marker; gusA, Escherichia coli beta-glucuronidase 
reporter gene; oriT, RK2-derived origin for conjugal plasmid transfer; T0T1, transcriptional 
terminators T0 and T1 from bacteriophage α and E. coli rrnB operon, respectively; Kmr, 
nptI gene coding for neomycin phosphotransferase, which confers kanamycin resistance; 
ori, E. coli pMB9 origin of replication; FRT, Flp recombinase target; aacC1, gentamycin 














































3.C.i. IDENTIFICATION OF THE PUTATIVE lysR FAMILY GENE adeL   
The analysis of the region upstream of adeMNO operon revealed the presence of 
a gene A1S_2303, it was named adeL. This gene was identified as the possible local 
regulator for AdeMNO efflux pump expression. Gene adeL from eight different A. 
baumannii isolates was sequenced, and these results were input into the Basic Local 
Alignment Search Tool (BLAST). The results indicated that this gene belongs to the lysR 
family of regulators (Fig. 3.7.).  
 
3.C.ii. PRESENCE OF adeL GENE IN THE CLINICAL ISOLATES OF A. baumannii 
The presence of the adeL gene, putative regulator for adeMNO, was determined 
by PCR technique. Eight of the eleven isolates of A. baumannii tested showed the 
presence of this gene (Fig. 3.8.). From those that tested positive, six were found to 
express adeN and three showed no expression of such a gene (Table 3.4.). The control 
strain A. baumannii ATCC19606 showed presence of the putative regulator gene, without 
showing expression of the pump operon (Fig. 3.1.). 
 
3.C.iii. SEQUENCE ANALYSIS OF adeL GENE 
Gene adeL from eight clinical isolates of A. baumannii strains was amplified using 
PCR and the products were sequenced. The alignment analysis of these sequences 
revealed differences in nucleotides between strains expressing the adeN, gene that 




(Fig. 3.9.). Exceptions to these results were A. baumannii ATCC19606 and the clinical 
isolate A. baumannii 59973. The adeL sequence obtained from the control strain was 
similar to the sequence found in strains expressing adeN, but in the expression study this 
strain showed no-expression of such a gene. In the case of A. baumannii isolate 59973 
the sequence for adeL was analogous to the group of isolates not expressing the adeN 























Figure 3.7. Three-dimensional structure prediction of AdeL Three-dimensional 
sturucture of AdeL protein was predicted using the Conserved domain database (CDD).  
The structure shows similarity to LysR-type transcriptional regulator (LTTR) proteins.  
Residues shown in red are similar/identical to the LTTR CrgA from Neisseria meningitide, 
























Figure 3.8. PCR-based detection of putative lysR family gene, adeL in various A. 
baumannii clinical isolates. 1. A. baumannii 63169; 2. A. baumannii 58352; 3. A. 
baumannii 59960; 4. A. baumannii 59973; 5. A. baumannii 64130; 6. A. baumannii 64153; 
7. A. baumannii 64797; 8. A. baumannii 63487; 9. A. baumannii 65239; 10. A. baumannii 



















Table 3.4. Presence and expression of adeN gene and the presence of adeL 
putative regulator. The results summarized in this table were obtained by PCR 
technique 
 
    +, indicate the positive detection of the gene and/ or its expression 
     -, indicate the negative detection of the gene and/or its expression in the strain.  
 adeN adeL 
Strain DNA mRNA DNA 
A. baumannii 63169 + + + 
A. baumannii 58352 + + - 
A. baumannii 59960 + - + 
A. baumannii 59973 + + - 
A. baumannii 64130 + - - 
A. baumannii 64153 + + + 
A. baumannii 64797 + - + 
A. baumannii 63487 + + + 
A. baumannii 65239 + + + 
A. baumannii 66310 + - + 
A. baumannii 66985 + + + 








Figure 3.9. DNA sequence analysis of putative LysR-family regulator encoding 
adeL from eight A. baumannii clinical isolates. Strains found to express the adeN 
gene are shown with an asterisk (*). Difference in nucleotides sequence between strains 
expressing and not expressing the adeN gene are underlined and in bold. Underlined 
strains showed a different tendency from the rest of the isolates studied, A. baumannii 
59973 was found to express the adeN gene in spite of its homology with the sequences 
of those strains that showed expression of adeN. In the case of A. baumannii 
ATCC19606, it did not show expression of the RND pump-encoding adeN gene even in 
absence of the nucleotide difference. Completed adeL sequences from the strains shown 


















3.C.iv. CREATION OF adeL GENE DELETION FRAGMENT  
A gene knock-out for the adeL regulator was created using the technique 
described by Choi and Schweizer (2005) with the purpose of studying adeL gene 
function in the native strains of A. baumannii. Annealing of the three amplicons 3’ and 5’ 
ends from adeL gene and aacC1 gene is described in Fig 3.10.A. permitted the 
construction of the gene deletion fragment for adeL gene, ΔadeL::Gm-FRT, as seen in 
Fig. 3.10.B. The pUC18 plasmid was digested with SmaI, and ligated with ΔadeL::Gm-
FRT, to obtain the pPLS036 plasmid and transformed into DH5α competent cells. PCR 
was used to screen the colonies for the presence of aacC1 gene and ΔadeL::Gm-FRT 
fragment, the results are shown in Fig. 3.11.A. and B respectively. A second screening 
was performed by restriction enzymes using EcoRI in a single digestion and a PstI/ KpnI 



















Figure 3.10. Schematic illustration adeL knock out fragment generation by overlap 
extension PCR. (A) During the first round PCR (PCR1), a 200 bp fragment from the 5' 
end and 250 bp fragment from the 3' ends of adeL were annealed together with aacC1 
using the splicing overlap extension reaction as described in section 2.9. (B) The 1.5 Kb 



























Figure 3.11. Cloning of ΔadeL::Gm-FRT fragment into pUC18 plasmid. The adeL 
gene deletion fragment obtained from the SOEing PCR reaction shown in Fig. 3.7. was 
ligated into pUC18 plasmid pre-digested with SmaI restriction enzyme. Screening of the 
resulting plasmids was performed by PCR and restriction digestion. Pictures A and B 
show the results of the screening PCR performed to detect the aacC1 gene and the 
ΔadeL::Gm-FRT fragment respectively. Gmr was detected using primers GmFRT_Dn 
and GmFRT_UP resulting in the amplification of a 1053 bp fragment. The presence of 
ΔadeL::Gm-FRT fragment was detected using primers Ab2303_F and Ab2303_R 
amplifying an amplicon of around 1.5 Kb. Picture C shows the digestion of the pPLS036 
plasmid with EcoRV which generated two fragments a 3029 bp and a 1163 bp. In the 
case of the double digestion with PstI/ KpnI shown in picture D, the results fragments 




















3.C.v. SEQUENCING AND ANALYSIS OF THE adeMNO PROMOTER REGION FROM 
A. baumannii ISOLATES 
The promoter regions from six clinical isolates were sequenced with the purpose 
of establishing possible differences between strains expressing and those not 
expressing the adeN gene. For this purpose, strains A. baumanni 63169, 64153 and 
63487 were selected as examples of strains expressing the adeN gene. In the case of  
the A. baumannii isolates which showed no expression of the gene, the isolates 59960, 
64797 and 66310 were selected for sequencing. The alignment of the six adeMNO 
promoter sequences indicated that there is a one nucleotide difference between these 

















Figure 3.12. Sequence alignment of adeMNO promoter region between nucleotides 
from six A. baumannii isolates. Strains marked with an asterisk correspond to strains 
that express adeN, and their sequences showed the presence of a Adenine (A) 
nucleotide in position 128 from the start codon of adeM, the nucleotide in this position is 
showed bold and underlined. The group of isolates that showed expression of the RND 
efflux pump gene presented a Guanidine (G) in this position instead. The signature 
sequence for the LysR-binding site is shown in the bottom of the alignment (Maddocks 












































A. EXPRESSION OF RND EFFLUX PUMPS IN CLINICAL ISOLATES OF 








It is now a widely accepted that RND efflux pumps play a major role in the 
antibiotic resistance of clinically relevant Gram-negative bacteria. Therefore, 
characterization of these pumps is essential in order to design effective drug therapy. A. 
baumannii is no exception and with increasing reports of multidrug resistance in this 
organism (Falagas et al., 2007; Navon-Venezia et al., 2007), this study intended to 
elucidate the role of RND pumps in its resistance. For this purpose, this research studied 
the expression of six RND efflux pump-encoding genes (characterized as well as yet 
uncharacterized) in clinical isolates of A. baumannii from Canadian hospitals. Since the 
expression of RND efflux pumps is usually under very tight regulatory control, this study 
identifies only the genes that are expressed either constitutively or under the 
experimental conditions. While the absence of the PCR product could indicate absence 
of the gene or its transcription, this could also result from inability of the experimental 
primers to anneal to their target gene as result of possible variations in the sequence. In 
spite of these limitations and the small sample size, this study provided convincing 
evidences that the expression of RND pumps is widespread in clinical isolates of A. 
baumannii, as well as confirmed the presence RND efflux pumps that are yet to be 
characterized in this organism. 
AdeABC and AdeIJK are the two major pumps described in A. baumannii 
(Damier-Piolle et al., 2007; Magnet et al., 2001). AdeABC has been shown to efflux 
amikacin, chloramphenicol, cefotaxime, erythromycin, gentamicin, kanamycin, 
norfloxacin, netilmicin, ofloxacin, perfloxacin, sparfloxacin, tetracycline, tobramycin, and 
trimethoprim (Magnet et al., 2001), while AdeIJK effluxes β-lactams, chloramphenicol, 
tetracycline, erythromycin, lincosamides, fluoroquinolones, fusidic acid, novobiocin, 
rifampin, trimethoprim, acridine, pyronine, safranin, and sodium dodecyl sulfate (SDS) 
(Damier-Piolle et al., 2007). Interestingly, the adeJ gene was in all of the 11 clinical 
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isolates from the study in contrast to the adeB gene that was found only in seven 
isolates, suggesting that AdeIJK is likely to be the major pump in these isolates. Also, 
five out of six clinical isolates that harbored both the adeB and adeJ genes, namely A. 
baumannii 63169, A. baumannii 59960, A. baumannii 64130, A. baumannii 64397, A. 
baumannii 63487, and A. baumannii 66985, expressed only one of the two genes. One 
exception was A. baumannii 64130 that was found to express both adeB and adeJ 
genes together (Table 3.1.). The AdeDE pump is the third pump previously described in 
A. baumannii that effluxes amikacin, ceftazidime, chloramphenicol, ciprofloxacin, 
erythromycin, ethidium bromide, meropenem, rifampin, and tetracycline (Chau et al., 
2004). From the 11 isolates tested, 10 were found to harbor the gene and 80% of those 
isolates were found to express the adeE gene (Table 3.1). All the strains used in this 
study were tested for their susceptibility to ceftazidime, ciprofloxacin, tetracycline, and 
chloramphenicol which are known substrates of the AdeDE pump (Chau et al., 2004), 
and the results are shown in Appendix 1.  According to these results, strains that 
expressed the adeE gene were not found to be any more resistant to these antibiotics 
than A. baumannii 66985 that did not contain the adeE gene. These observations could 
be the result of overlapping substrate which makes difficult to identify the subtrates efflux 
by this pump. Also there is a possibility that this RND pump was not functional in these 
strains, this could be caused by the lack of its outer membrane protein or by presence of 
a defective sequence of the operon. In this case more research is necessary in order to 
validate any of these explanations. 
 A result that is important to mension is the detection of adeB and adeE genes 
together in A. baumannii isolates analysed during this study. From the six strains 
harbouring both genes, three of them showed concurrent expression, this observation is 
unique and has not been reported in literature. Therefore, more research is needed to 
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understand the implication of these results in the resistance mechanism present in this 
pathogen.  Further analyses including Southern blot analysis are required to confirm the 
concurrent presence of the entire adeABC and adeDE operons in A. baumannii strains. 
The clinical isolates of A. baumannii were also tested for the presence and 
expression of three uncharacterized RND pump encoding genes, namely A1S_2818, 
A1S_3217, and adeN that are part of the A1S_2817-2818, A1S_3219-3218-3217-3214, 
and adeMNO operons, respectively. The A1S_2817-2818 operon consists of genes 
encoding the MF (A1S_2817) and the RND (A1S_2818) proteins, but not for the OMF. 
The A1S_2818 gene was found to be present in six out of 11 isolates tested (55%), 
while five out those six isolates were found to be expressing the gene.  Two possible 
homologs of the OMF-encoding genes were found in the genome of A. baumannii 
ATCC17989, A1S_0255 and A1S_1241. It is possible that A1S_2817-2818 utilizes one 
of the gene products as its outer membrane component. It is also possible that 
A1S_2817-2818 functions with one of the outer membrane proteins that is encoded as a 
part of RND complex operons in a fashion similar to the MexXY pump of P. aeruginosa, 
which functions with the OprM protein that is encoded as part of the mexAB-oprM 
operon (Mine et al., 1999).  
The A1S_3219-3218-3217-3214 operon is different from other RND complex 
encoding operons because it contains two genes encoding the OMF (A1S_3219 and 
A1S_3214), as shown in Fig. 1.2.  If A1S_3218-3217 is a functional pump, having two 
outer membrane proteins can possibly result in a wider substrate range for this pump. 
An example of this type alternative structure is MexJK pump which is able to function 
with OpmH or OprM outer membrane proteins, this flexible tripartite assembly allows the 
pump to efflux different substrates depending on the outer membrane forming the 
complex (Chuanchuen et al., 2005). However, the A1S_3217 gene was found to be 
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present and expressed in only A. baumannii 64130, suggesting that it may not be of 
significant clinical relevance. 
The purpose of this part of the study was to examine the expression of different 
RND pump encoding genes in clinical isolates of A. baumannii; the results indicated that 
the clinical isolates of A. baumannii extensively express RND efflux pumps. The lack of 
conclusive correlations between efflux pump expression and the antibiotic 
susceptibilities of clinical isolates of A. baumannii is most likely due to concurrent 
expression of multiple pumps and/or due to the presence of other resistance 
mechanisms. As for the gene products for the yet uncharacterized genes, the lack of 
correlation could be connected to the possibility that the drugs tested during this 
research were not substrates of these pumps or maybe to the lack of a functional pump 
structure. This study also indicated that as yet uncharacterized pumps may play an 
important role as part of the antibiotic resistance mechanism of A. baumannii, since at 
least two of the three uncharacterized pumps were found to be expressed in a large 
proportion of clinical isolates. 
The results obtained durig this study support the idea that RND pumps played an 
essential role in the antibiotic resistance mechanism present in Gram-negative bacteria, 
suggesting that energy-dependent efflux system should be considered while designing 























Expression analysis of the RND pumps from clinical isolates of A. baumannii 
showed that the operon A1S_2304-A1S_2305-A1S_2306, designated as AdeMNO in 
this study, was present in all of the isolates tested showing expression in 8 out of the 11 
isolates tested.These results point to the necessity of characterizing this RND efflux 
pump, in order to further investigate its role in the antibiotic resistance mechanism of 
emergent MDR A. baumannii. This was accomplished using a surrogate P. aeruginosa 
strain PAO750 which presents the advantage of lacking its native RND efflux systems; 
this allowed the functional characterization of the AdeMNO efflux pump without 
interferences. The AdeMNO pump was found to efflux clinically-relevant antibiotics, 
chloramphenicol, trimethoprim, and clindamycin. Preliminary screening using Vitek 2 
system also showed imipenem as substrate for this pump, but posterior analysis by disc 
diffusion technique discarded this possibility. 
As mentioned above, the adeN gene was found in all of the clinical isolates 
studied, as well as the control strain, A. baumannii ATCC19606.  None of the previously 
characterized pumps (AdeABC, AdeDE, AdeIJK) were found to be as prevalent in the 
clinical isolates, and even though the expression levels of this gene were lower than the 
adeB and adeJ genes, the presence of the adeN gene in 100% of the isolates tested 
suggests that this pump may be of clinical and/or physiological significance in A. 
baumannii.  Indeed, a BLAST search for the adeMNO operon reveals that it is present in 
all strains of A. baumannii that have been sequenced (either partially or completely) to 
date, including the pathogenic strains A. baumannii AYE (Vallenet et al., 2008), A. 
baumannii ACICU (Iacono et al., 2008), and A. baumannii AB900, and also the human 
louse symbiont A. baumannii SDF (Vallenet et al., 2008), in addition to A. baumannii 
ATCC17989 (Smith et al., 2007) and A. baumannii ATCC19606 (PATRIC, Pathosystems 
Resource Integration Center, Virginia Bioinformatics Institute). 
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Among RND pumps characterized from other bacterial species, the closest 
homolog of AdeN is the BpeF protein from BpeEF-OprC efflux system of Burkholderia 
pseudomallei (Kumar et al., 2006) and the CeoB protein from CeoAB-OpcM  efflux 
system of Burkholderia cenocepacia (Nair et al., 2004).  The BpeEF-OprC and CeoAB-
OpcM systems have both been shown to efflux trimethoprim and chloramphenicol, but 
not clindamycin.  A number of clinical isolates used in this study were found to be 
resistant to various antibiotics (Appendix 1); including substrates of the AdeMNO pump 
(chloramphenicol, trimethoprim, and clindamycin).  However, it was impossible to 
ascertain the role of AdeMNO in the antibiotic resistance of the clinical isolates due to 
the simultaneous expression of multiple RND efflux pump genes. 
 The AHL assay performed in this study established that the AdeMNO pump 
introduced in the surrogate strain of P. aeruginosa not only effluxes the antibiotics 
mentioned above, but also its presence results in increased efflux of AHL. N-Acyl 
homoserine lactone is a group of compounds utilized by bacteria as quorum sensing 
molecule; this biological signal trigger a synchronized respond of the microorganism 
based in population density (Chan et al., 2007). This is an interesting finding since it 
opens the possibility that the AdeMNO pump plays a physiological role in biofilm 
formation by A. baumannii.  Although previous reports have shown that RND pumps are 
involved in the efflux of cell signalling molecules in bacteria (Kohler et al., 2001; Tian et 
al, 2009a), this has not been described for any of the characterized efflux pumps of A. 
baumannii. Further studies are necessary to determine the role of AdeMNO in cell-to-cell 
communication, biofilm formation and secretion in A. baumannii.  
To summarize, this study identified and characterized AdeMNO, a novel RND 
efflux pump of A. baumannii that is able to efflux clinical relevant antibiotics as well as 
AHL, a quorum sensing signalling molecule in P. aeruginosa PA008.  Since this pump 
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was found to be present in all of the clinical isolates tested in this study, with its 
expression observed in a very high proportion of the isolates, it is likely to be of clinical 






























The last objective of this thesis was to study the regulatory mechanisms involved 
in the expression of the AdeMNO pump. It is known that efflux pumps decrease the 
antibacterial efficiency of structurally unrelated substances, by limiting the accumulation 
of these compounds in the bacteria cytoplasm (Borst et al., 1999; Koronakis et al., 2000; 
Borges-Walmsley et al., 2003). The overexpression of these proteins can be responsible 
for an extended cross-resistance that can confer low sensitivity to a variety of drug types 
(Coyne et al., 2010; Lin et al., 2009). As a consequence, the identification and 
understanding of the transcription regulation system associated with RND efflux pumps 
could result in the creation or discovery of molecules to repress their expression allowing 
the inactivation of the efflux system, decreasing the resistance of this pathogen. 
In this study, examination of the upstream region of the adeMNO operon of A. 
baumannii revealed the presence of a lysR-type open reading frame. In Gram-negative 
bacteria, a publication described this type of regulator associated with the expression of 
the MexEF-OprN operon in P. aeruginosa (Kohler et al., 1999) and BpeEF-OprC in 
Burkholderia pseudomallei (Kumar et al., 2006). LysR-family transcription regulator is 
widely spread among prokaryotes associated to a diversity of genes and complex 
regulons, but this is the first time described in connection to RND efflux pumps operons 
in A. baumannii. 
The analysis of the adeL sequences obtained from multiple A. baumannii clinical 
isolates showed differences in sequence between strains expressing and those not 
expressing adeN gene. These nucleotide replacements were all identified in the wobble 
base, so none of them translated into amino acids substituted in the resulting protein. 
This observation suggests that the differences found in the adeN gene expression is not 
related with the amino acids constituent of the adeL, but may be connected with the 
nucleotide sequence that encodes the protein. According to the available literature, a 
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single nucleotide variation in the third base of a codon that encodes the same amino 
acid could result in fluctuation of the gene expression (Kudla et al., 2009). This control 
could be explained by codon bias, in which the efficiency of the gene translation and 
accuracy correlates with the abundance of the isoaccepting tRNA (Zuckerkandl and  
Pauling, 1965; Ikamura, 1985). In addition, recent research has stablished that mRNA 
folding near the ribosomal binding site affects the levels of a protein expression (Kudla et 
al., 2009).  In the case of adeL, if the nucleotide substitutions found in its sequence 
alters the proper mRNA folding affecting its interaction with the ribosomal structure, this 
could result in fluctuations of the transcription leves of the regulator, causing variations in 
the levels of adeMNO transcription. 
In addition to the sequence differences found in the regulator adeL region, the 
analysis of the promoter region of six isolates of A. baumannii revealed the existence of 
a single nucleotide variation between strains expressing and those not expressing the 
adeN gene. As seen Fig. 3.12., the recognized as the promoter region for adeM gene 
showed a one base substitution of a G for an A in the nucleotide 128 up-stream  from 
adeMNO start codon. It is possible that the adeL regulator binds tighter to the DNA 
sequence of the promoter region in presence of a Guanine (G) nucleotide resulting in the 
repression of the transcription of adeN. 
Another characteristic of LysR-family regulator that must be considered when 
attenting to explain the difference in the adeN transcription, is the possibility of multiple 
binding sites within the promoter region associated to the adeMNO operon. Several 
reports have shown that  the LysR-type of transcription regulator could bind 
simultaneously to multiples sites within the intergenic region between the regulator 
sequence and the associated gene or operon (Belitsky et al., 1995; Lochoswska et al., 
2001; Porrua et al., 2007). This family of regulators has been reported as functionally 
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active as tetramer, and DNase-I protection assay studies support the multibinding 
capacity of the LysR polymer proteins (Muraoka et al., 2003). This function could result 
in the bending of the DNA strand interfering with the DNA-RNA-polymerase interaction 
modulating the gene transcription (Lochowska et al., 2004).  
In summary, many questions remain unanswered in relation to the transcription 
regulation mechanism(s) associated not only with the adeMNO operon, but also with 
RND efflux pumps from A. baumannii. This study has made the novel discovery of AdeL, 
a LysR-transcription regulator associted to adeMNO. The study of the adeL sequence, 
as well as the promoter region from different A. baumannii isolates revealed variations in 
nucleotide sequence that could explain the differences in the adeN expression observed 





























The creation of a deletion mutant of adeMNO is essential in order to confirm the 
substrate profile of this pump. A gene deletion construct for adeMNO was prepared 
utilizing a SOEing reaction as seen in Fig. 2.1. This product was ligated into a 
mobilizable pEXKm5 vector (Fig. 3.6) to be used as delivery plasmid. There are various 
advantages associated with the use of this plasmid; it contains multiples cloning sites 
inserted into the LacZα gene that facilitate the recombinant recognition, it possesses a 
constitutively expressed gusA gene which allows the visual recognition of the 
merodiploids, and lastly, the presence of a resolution element sacB gene that works as a 
counterselection marker faciliates the curing of the plasmid (Lopez et al., 2009). In 
addition, this plasmid possesses the nptII gene encoding for neomycin 
phosphotransferase, which confers kanamycin resistance making easy the manipulation 
and identification of mutants containing pEX-based plasmid (Choi et al., 2008). A. 
baumannii will be used to conjugate a mutant strain containing the pEXKm5-
ΔadeMNO::Gm-FRT plasmid followed by the flipping of Gm marker. This A. baumannii 
mutant will lack a functional AdeMNO efflux pump facilitating the verification of the 
substrate profile obtained in the P. aeruginosa PA008.  
Gene adeL, located downstream from adeMNO, was identified as the possible 
local regulator for this pump operon, nevertheless this association could be confimed by 
the use of the homologous recombination technique highlighted above. The innactivation 
of AdeL in A. baumannii will verify the role of this gene in the regulation of adeMNO 
expression, as well as to gather details about the nature of this control.  
In summary, more research is required in order to understand the relation 
between adeL and promoter sequence variations and the pump expression. All this 
information is indispensable to understand and resolve the increasing resistance 
observed among clinical isolates. This research has provided exciting results associated 
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with RND efflux pump in A. baumannii, nevertheless more research is required before 
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Appendix 1. Antibiotic Susceptibilities of A. baumannii Clinical Isolates Used in this Study 
 
Strain / Antibiotic City Ap A/C PIP CXM CXM-
AX 
CTX CAZ AMK Gm TOB CIP TCN NF SXT 
A. baumannii 63169 Winnipeg >32 4 8 32 32 8 8 16 8 2 1 4 >512 <20 
A. baumannii 58352 Winnipeg 16 4 8 16 16 8 4 <2 <1 <1 <0.25 2 256 <20 
A. baumannii 59960 Vancouver >32 4 8 >64 >64 16 16 <2 <1 <1 1 4 >512 <20 
A. baumannii 59973 Vancouver >32 8 16 >64 >64 16 16 <2 <1 <1 <0.25 <1 >512 <20 
A. baumannii 64130 Hamilton 16 4 8 16 16 8 4 <2 <1 <1 <0.25 <1 >512 <20 
A. baumannii 64153 Hamilton 16 4 8 16 16 8 <1 8 <1 <1 <0.25 2 >512 <20 
A. baumannii 64397 Vancouver 16 4 8 >64 >64 16 4 <2 <1 <1 0.5 2 >512 >320 
A. baumannii 63487 Winnipeg >32 4 8 32 32 8 8 8 8 <1 1 4 >512 <20 
A. baumannii 65239 Victoria >32 4 16 >64 >64 16 8 <2 <1 <1 <0.25 <1 >512 <20 
A. baumannii 66310 Vancouver 16 4 8 32 32 8 16 4 8 <1 1 4 256 <20 
A. baumannii 66985 Montreal 16 4 16 >64 >64 16 4 <2 <1 <1 0.5 2 >512 <20 
A. baumannii 
ATCC19606 
NA >32 16 32 >64 >64 16 8 <2 4 <1 1 <1 128 80 
Ap, Ampicillin; A/C, Amoxicillin/Clavulanic Acid; PIP, Piperacillin; CXM,Cefuroxime;   CXM-AX, Cefuroxime Axetil; CTX,  
Cefotaxime; CAZ, Ceftazidime; AMK, Amikacin; Gm, Gentamicin; TOB, Tobramycin; CIP, Ciprofloxacin; TCN, Tetraciclyne;   
NF, Nitrofurantoin; SXT, Trimethoprim-sulfamethoxazole 
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Appendix 2. Sequence alignment of adeL from A. baumannii isolates. Differences in 






63169       GGGTTTACCGCGTGCTTCTGTGACTACAACCATTCAGGCTTTAGAGAAGCATTTACAAGT 
59960       GGGTTTACCGCGTGCTTCTGTGACCACAACTATTCAGGCTTTAGAGAAGCATTTACAAGT 
59973       GGGTTTACCGCGTGCTTCTGTGACCACAACTATTCAGGCTTTAGAGAAGCATTTACAAGT 
64153       GGGTTTACCGCGTGCTTCTGTGACCACAACCATTCAGGCTTTAGAGAAGCATTTGCAAGT 
64797       GGGTTTACCGCGTGCTTCTGTGACCACAACTATTCAGGCTTTAGAGAAGCATTTACAAGT  
63487       GGGTTTACCGCGTGCTTCTGTGACTACAACCATTCAGGCTTTAGAGAAGCATTTACAAGT  
66310       GGGTTTACCGCGTGCTTCTGTGACCACAACTATTCAGGCTTTAGAGAAGCATTTACAAGT  
66985       GGGTTTACCGCGTGCTTCTGTGACTACAACCATTCAGGCTTTAGAGAAGCATTTACAAGT 
ATCC19606   GGGTTTACCGCGTGCTTCTGTGACTACAACCATTCAGGCTTTAGAGAAGCATTTACAAGT 
 ***********************  ***** *********************** *****  
 
63169       TCGTTTGCTGAATCGAACAACACGAAAAATTAGTCTCACACCGGATGGCGCGGTATATTA 
59960       TCGTTTGCTGAATCGGACAACACGAAAAATTAGTCTCACACCGGATGGCGCCGTATATTA 
59973       TCGTTTGCTGAATCGGACAACACGAAAAATTAGTCTCACACCGGATGGCGCCGTATATTA 
64153       TCGATTGCTTAATCGGACAACACGAAAAATTAGTCTCACACCGGATGGCGCCGTATATTA 
64797       TCGTTTGCTGAATCGGACAACACGAAAAATTAGTCTCACACCGGATGGCGCCGTATATTA 
63487       TCGTTTGCTGAATCGAACAACACGAAAAATTAGTCTCACACCGGATGGCGCGGTATATTA  
66310       TCGTTTGCTGAATCGGACAACACGAAAAATTAGTCTCACACCGGATGGCGCCGTATATTA 
66985       TCGATTGCTTAATCGGACAACACGAAAAATTAGTCTCACACCGGATGGCGCCGTATATTA 
ATCC19606   TCGATTGCTTAATCGGACAACACGAAAAATTAGTCTCACACCGGATGGCGCCGTATATTA 
           *** ***** ***** *********************************** ******** 
 
63169       TGATCGGACAGCCCGTATTTTAGCGGATGTTTCCGATATTGAATCTTCTTTTCATGATGC 
59960       TGATCGGACAGCCCGTATTTTAGCGGATGTTTCCGATATTGAATCTTCCTTTCATGATGC 
59973       TGATCGGACAGCCCGTATTTTAGCGGATGTTTCCGATATTGAATCTTCCTTTCATGATGC 
64153       TGATCGGACAGCCCGTATTTTAGCGGATGTTGCCGATATTGAATCTTCTTTTCATGATGC 
64797       TGATCGGACAGCCCGTATTTTAGCGGATGTTTCCGATATTGAATCTTCCTTTCATGATGC 
63487       TGATCGGACAGCCCGTATTTTAGCGGATGTTTCCGATATTGAATCTTCTTTTCATGATGC 
66310       TGATCGGACAGCCCGTATTTTAGCGGATGTTTCCGATATTGAATCTTCCTTTCATGATGC 
66985       TGATCGGACAGCCCGTATTTTAGCCGATGTTGCCGATATTGAATCTTCTTTTCATGATGC 
ATCC19606   TGATCGGACAGCCCGTATTTTAGCGGATGTTGCCGATATTGAATCTTCTTTTCATGATGC 
              ************************ ****** **************** *********** 
 
63169       AGAGCGAGGGCCGAGAGGTCAGCTTCGTATTGATGTGCCTGTATCGATTGGCCGTTTAAT 
59960       AGAGCGGGGGCCAAGGGGTCAGCTTCGTATTGATGTGCCTGTATCGATTGGCCGTTTAAT 
59973       AGAGCGGGGGCCAAGGGGTCAGCTTCGTATTGATGTGCCTGTATCGATTGGCCGTTTAAT 
64153       AGAGCGGGGGCCAAGAGGTCAGCTTCGTATTGATGTGCCTGTATCGATTGGACGTTTAAT 
64797       AGAGCGGGGGCCAAGAGGTCAGCTTCGTATTGATGTGCCTGTATCCATTGGCCGTTTAAT 
63487       AGAGCGAGGGCCGAGAGGTCAGCTTCGTATTGATGTGCCTGTATCGATTGGCCGTTTAAT 
66310       AGAGCGGGGGCCAAGAGGTCAGCTTCGTATTGATGTGCCTGTATCCATTGGCCGTTTAAT 
66985       AGAGCGGGGGCCAAGAGGTCAGCTTCGTATTGATGTGCCTGTGTCCATTGGCCGTCTAAT 
ATCC19606   AGAGCGGGGGCCAAGAGGTCAGCTTCGTATTGATGTGCCTGTATCGATTGGACGTTTAAT 









63169       TTTAATTCCAAGACTACGCGATTTTCATGCACGCTATCCTGATATTGATTTAGTGATTGG 
59960       TTTAATTCCAAGACTACGCGATTTTCATGCACGCTATCCTGATATTGATTTAGTGATTGG 
59973       TTTAATTCCAAGACTACGCGATTTTCATGCACGCTATCCTGATATTGATTTAGTGATTGG 
64153       TTTAATTCCAAGGCTCCGCGATTTTCATGCACGCTATCCTGATATTGATTTAGTAATTGG 
64797       TTTAATTCCAAGACTACGCGATTTTCATGCACGCTATCCTGATATTGATTTAGTGATTGG 
63487       TTTAATTCCAAGACTACGCGATTTTCATGCACGCTATCCTGATATTGATTTAGTGATTGG 
66310       TTTAATTCCAAGACTACGCGATTTTCATGCACGCTATCCTGATATTGATTTAGTGATTGG 
66985       TTTAATTCCAAGGCTCCGCGATTTTCATGCACGCTATCCTGATATTGATTTAGTAATTGG 
ATCC19606   TTTAATTCCAAGGCTCCGCGATTTTCATGCACGCTATCCTGATATTGATTTAGTGATTGG 
              ************  ** ************************************** *****  
  
63169       TCTAAATGACCGACCTGTAGACTTGGTTGGAGAAGCAGTTGATTGTGCAATTCGGGTGGG 
59960       TCTAAATGACCGACCTGTAGACTTGGTGGGAGAGGCTGTCGATTGTGCAATTCGGGTCGG 
59973       TCTAAATGACCGACCTGTAGACTTGGTGGGAGAGGCTGTCGATTGTGCAATTCGGGTCGG 
64153       TCTGAACGACCGACCTGTAGACTTGGTTGGAGAAGCGGTTGATTGTGCAATTCGGGTGGG 
64797       TCTAAATGACCGACCTGTAGACTTGGTGGGAGAGGCTGTCGATTGTGCAATTCGGGTCGG 
63487       TCTAAATGACCGACCTGTAGACTTGGTTGGAGAAGCAGTTGATTGTGCAATTCGGGTGGG 
66310       TCTAAATGACCGACCTGTAGACTTGGTGGGAGAGGCTGTCGATTGTGCAATTCGGGTCGG 
66985       TCTGAATGACCGACCTGTAGACTTGGTTGGAGAAGCAGTTGATTGTGCAATTCGGGTGGG 
ATCC19606   TCTGAACGACCGACCTGTAGACTTGGTTGGAGAAGCGGTTGATTGTGCAATTCGGGTGGG 
               ***  ** ********************^*****^**^**^****************^** 
 
63169       AGAATTAAAAGATTCAAGCTTAATTGCGCGTCGTATCGGAACTTTCCAGTGCGCAACCGC 
59960       TGAATTAAAAGATTCAAGCTTAATTGCGCGTCGTATCGGAACTTTCCAGTGTGCAACTGC 
59973       TGAATTAAAAGATTCAAGCTTAATTGCGCGTCGTATCGGAACTTTCCAGTGTGCAACTGC 
64153       TGAATTAAAAGATTCAAGCTTAATTGCGCGTCGTATCGGAACTTTCCAGTGTGCAACTGC 
64797       TGAATTAAAAGATTCAAGCTTAATTGCGCGTCGTATCGGAACTTTCCAGTGTGCAACTGC 
63487       AGAATTAAAAGATTCAAGCTTAATTGCGCGTCGTATCGGAACTTTCCAGTGCGCAACCGC 
66310       TGAATTAAAAGATTCAAGCTTAATTGCGCGTCGTATCGGAACTTTCCAGTGTGCAACTGC 
66985       TGAATTAAAAGATTCCAGCTTAATTGCGCGTCGTATCGGAACTTTCCAGTGTGCAACTGC 
ATCC19606   TGAATTAAAAGATTCAAGCTTAATTGCGCGTCGTATCGGAACTTTCCAGTGTGCAACAGC 
           ************** ***************************************** ** 
 
63169       TGCTTCACCGATTTATTTAGAAAAATATGGCGAACCTACCTCAATTGAAGATTTGCAAAA 
59960       TGCTTCACCGATTTATTTAGAAAAATATGGCGAACCTACCTCAATTGAAGATTTGCAAAA 
59973       TGCTTCACCGATTTATTTAGAAAAATATGGCGAACCTACCTCAATTGAAGATTTGCAAAA 
64153       TGCTTCACCGATTTATTTAGAAAAATATGGCGAACCTACCTCAATTGAAGATTTGCAAAA 
64797       TGCTTCACCGATTTATTTAGAAAAATATGGCGAACCTACCTCAATTGAAGATTTGCAAAA 
63487       TGCTTCACCGATTTATTTAGAAAAATATGGCGAACCTACCTCAATTGAAGATTTGCAAAA 
66310       TGCTTCACCGATTTATTTAGAAAAATATGGCGAACCTACCTCAATTGAAGATTTGCAAAA 
66985       TGCTTCACCGATTTATTTAGAAAAATATGGCGAACCTACCTCAATTGAAGATTTGCAAAA 
ATCC19606  TGCTTCACCGATTTATTTAGAAAAATATGGCGAACCTACCTCAATTGAAGATTTGCAAAA 

















63169       AAACCATAAAGCGATTCACTTCTTTTCAAGCCGTACCGGACGCAACTTCGATTGGGACTT  
59960       AAACCATAAAGCGATTCACTTCTTTTCAAGCCGTACCGGACGCAACTTCGATTGGGACTT  
59973       AAACCATAAAGCGATTCACTTCTTTTCAAGCCGTACCGGACGCAACTTCGATTGGGACTT  
64153       AAATCATAAAGCGATTCACTTCTTTTCAAGCCGTACCGGACGCAACTTCGATTGGGACTT  
64797       AAACCATAAAGCGATTCACTTCTTTTCAAGCCGTACCGGACGCAACTTCGATTGGGACTT  
63487       AAACCATAAAGCGATTCACTTCTTTTCAAGCCGTACCGGACGCAACTTCGATTGGGACTT  
66310       AAACCATAAAGCGATTCACTTCTTTTCAAGCCGTACCGGACGCAACTTCGATTGGGACTT  
66985       AAATCATAAAGCGATTCACTTCTTTTCAAGCCGTACCGGACGCAACTTCGATTGGGACTT 
ATCC19606  AAATCATAAAGCGATTCACTTCTTTTCAAGCCGTACCGGACGCAACTTCGATTGGGACTT  
           *** ********************************************************  
 
63169       TGTGGTTGATGATTTAATTAAAAGTGTGTCAGTACGTGGACGTGTTTCTGTAAATGACGG  
59960       TGTGGTTGATGACTTAATTAAAAGTGTATCAGTACGTGGACGTGTTTCGGTAAATGACGG  
59973       TGTGGTTGATGACTTAATTAAAAGTGTATCAGTACGTGGACGTGTTTCGGTAAATGACGG  
64153       TGTGGTTGATGATTTAATTAAAAGTGTGTCAGTACGTGGACGTGTTTCGGTAAATGACGG  
64797       TGTCGTTGATGATTTAATTAAAAGTGTGTCAGTACGTGGACGTGTTTCGGTAAATGACGG  
63487       TGTGGTTGATGATTTAATTAAAAGTGTGTCAGTACGTGGACGTGTTTCTGTAAATGACGG  
66310       TGTCGTTGATGATTTAATTAAAAGTGTGTCAGTACGTGGACGTGTTTCGGTAAATGACGG  
66985       TGTGGTTGATGATTTAATTAAAAGTGTGTCAGTACGTGGACGTGTTTCGGTAAATGACGG 
ATCC19606  TGTGGTTGATGATTTAATTAAAAGTGTGTCAGTACGTGGACGTGTTTCGGTAAATGACGG 
           *** ******** ************** ******************************* 
 
63169       GATGCTTATATCGACTTGGCTTTACAAGGTTTCGGTATAATTCAAGGTCCACGTTATAT  
59960       TGATGCTTATATCGACTTGGCTTTGCAAGGTTTCGGTATAATTCAAGGCCCACGTTATAT  
59973       TGATGCTTATATCGACTTGGCTTTGCAAGGTTTCGGTATAATTCAAGGCCCACGTTATAT  
64153       TGATGCTTATATCGACTTGGCTTTGCAAGGTTTTGGTATAATTCAAGGCCCACGTTATAT  
64797       TGATGCTTACATCGACTTGGCTTTGCAGGGTTTCGGTATAATTCAAGGCCCACGTTATAT  
63487       TGATGCTTATATCGACTTGGCTTTACAAGGTTTCGGTATAATTCAAGGTCCACGTTATAT  
66310       TGATGCTTACATCGACTTGGCTTTGCAGGGTTTCGGTATAATTCAAGGCCCACGTTATAT 
66985       TGATGCTTATATCGACTTGGCTTTGCAAGGTTTTGGTATAATTCAAGGCCCACGTTATAT 
ATCC19606  TGATGCTTATATCGACTTGGCTTTGCAAGGTTTTGGTATAATTCAAGGCCCACGTTATAT 
           ********* ************** ** ***** ************** *********** 
  
63169       GCTCACCAACCATTTAGAATCGGGTTTGTTAAAAGAAGTATTACCTCAGTGGACGCCAGC 
59960       GCTCACCAACCATTTAGAATCGGGTTTGTTAAAAGAAGTATTGCCTCAGTGGACGCCAGC  
59973       GCTCACCAACCATTTAGAATCGGGTTTGTTAAAAGAAGTATTGCCTCAGTGGACGCCAGC  
64153       GCTCACCAACCATTTAGAATCAGGTTTATTAAAAGAGGTATTGCCTCAGTGGACGCCAGC  
64797       GCTCACCAACCATTTAGAATCGGGTTTGTTAAAAGAAGTATTGCCTCAGTGGACGCCAGC  
63487       GCTCACCAACCATTTAGAATCGGGTTTGTTAAAAGAAGTATTACCTCAGTGGACGCCAGC  
66310       GCTCACCAACCATTTAGAATCGGGTTTGTTAAAAGAAGTATTGCCTCAGTGGACGCCAGC  
66985       GCTCACCAACCATTTAGAATCAGGTTTGTTAAAAGAGGTATTGCCTCAGTGGACGCCAGC 
ATCC19606  GCTCACCAATCATTTAGAATCAGGTTTGTTAAAAGAGGTATTGCCTCAGTGGACGCCAGC 








63169       GCCGATGCCAATTTCAGCAGTTTATCTTCAAAATCGTCATTTATCGCTCAAAGTAAAAGT  
59960       ACCGATGCCAATTTCAGCAGTTTATCTTCAAAATCGTCATTTATCGCTCAAAGTAAAAGT  
59973       ACCGATGCCAATTTCAGCAGTTTATCTTCAAAATCGTCATTTATCGCTCAAAGTAAAAGT  
64153       GCCGATGCCGATTTCAGCAGTTTATCTTCAAAATCGTCATTTATCGCTTAAAGTAAAAGT  
64797       GCCGATGCCGATTTCAGCAGTTTATCTTCAAAATCGTCATTTATCACTCAAAGTAAAAGT  
63487       GCCGATGCCAATTTCAGCAGTTTATCTTCAAAATCGTCATTTATCGCTCAAAGTAAAAGT  
66310       GCCGATGCCGATTTCAGCAGTTTATCTTCAAAATCGTCATTTATCACTCAAAGTAAAAGT  
66985       ACCGATGCCGATTTCAGCAGTTTATCTTCAAAATCGTCATTTATCGCTTAAAGTAAAAGT 
ATCC19606  ACCGATGCCGATTTCAGCAGTTTATCTTCAAAATCGTCATTTATCGCTTAAAGTAAAAGT 
                *********  *********************************** ** *********** 
  
63169       GTTTGTAGATTGGGTCGCTGAACTTTTTGCAGGTTGTCCATTACTTGGCGGTACGGCTTT  
59960       GTTTGTAGATTGGGTCGCTGAACTTTTTGCAGGTTGTCCATTACTTGGCGGTACGGCTTT  
59973       GTTTGTAGATTGGGTCGCTGAACTTTTTGCAGGTTGTCCATTACTTGGCGGTACGGCTTT  
64153       GTTTGTAGATTGGGTCGCTGAACTTTTTGCAGGCTGTCCATTACTTGGCGGTACAGCTTT  
64797       GTTTGTAGATTGGGTCGCTGAACTTTTTGCAGGTTGTCCATTACTTGGCGGTACGGCTTT  
63487       GTTTGTAGATTGGGTCGCTGAACTTTTTGCAGGTTGTCCATTACTTGGCGGTACGGCTTT  
66310       GTTTGTAGATTGGGTCGCTGAACTTTTTGCAGGTTGTCCATTACTTGGCGGTACGGCTTT  
66985       GTTTGTTGATTGGGTCGCTGAACTTTTTGCAGGCTGTCCATTACTTGGCGGTACAGCTTT 
ATCC19606  GTTTGTAGATTGGGTCGCTGAACTTTTTGCAGGCTGTCCATTACTTGGCGGTACAGCTTT 
            ****** ************************** ******************** ***** 
 
63169       ACCTTTCGACCAGAAATGTGAATTTGCCTGTGATAAAGAAACTGGTCATGAATATACAAT  
59960       ACCTTTCGACCAGAAATGTGAATTTGCCTGTGATAAAGAAACTGGTCATGAATATACAAT 
59973       ACCTTTCGACCAGAAATGTGAATTTGCCTGTGATAAAGAAACTGGTCATGAATATACAAT  
64153       ACCTTTCGACCAGAAATGTGAATTTGCCTGTGATAAAGAAACTGGTCATGAATATACAAT  
64797       ACCTTTCGACCAGAAATGTGAATTTGCCTGTGATAAAGAAACTGGTCATGAATATACAAT  
63487       ACCTTTCGACCAGAAATGTGAATTTGCCTGTGATAAAGAAACTGGTCATGAATATACAAT  
66310       ACCTTTCGACCAGAAATGTGAATTTGCCTGTGATAAAGAAACTGGTCATGAATATACAAT  
66985       ACCTTTCGACCAGAAATGTGAATTTGCCTGTGATAAAGAAACTGGTCATGAATATACAAT 
ATCC19606  ACCTTTCGATCAGAAATGTGAATTTGCCTGTGATAAAGAAACTGGTCATGAATATACAAT 
           ********* ************************************************** 
  
63169       CGTACTTTGGTCGAGCAGCACAATAT---------------------------------  
59960       TCGTACTTTGGTCGAGCAGCACAATAT---------------------------------  
59973       TCGTACTTTGGTCGAGCAGCACAATAT---------------------------------  
64153       TCGTACTTTGGTCGAGCAGCATAATAT---------------------------------  
64797       TCGTACTTTGGTCGAGCAGCACAATAT---------------------------------  
63487       TCGTACTTTGGTCGAGCAGCACAATAT---------------------------------  
66310       TCGTACTTTGGTCGAGCAGCACAATAT---------------------------------  
66985       TCGTACTTTGGTCGAGCAGCATAATAT--------------------------------- 
ATCC19606  TCGTACTT---------------------------------------------------- 




Appendix 3.  Sequence alignment from promoter region of six A. baumannii 
solates. Strains marked with asterisk showed expression of the adeN, those strains 
without it correspond to isolates that showed lack of expression of this gene. The one 
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